Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia

D. Beyene, A. Aseffa, D. Kidane, M. Macdonald, P. R. Klatser, G. A. Bjune, William Cairns Stewart Smith, M. Harboe

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The number of registered leprosy patients world-wide has decreased dramatically after extensive application of WHO recommended Multiple Drug Therapy (MDT). The annual number of new cases has, however, been almost unchanged in several populations, indicating that the infection is still present at community level. Nasal carriage of Mycobacterium leprae DNA was studied in Lega Robi village in Ethiopia. MDT had been applied for more than ten years, and 718 residents over 5 years old were eligible for the study. During the first survey nasal swab samples were collected from 664 (92.5%) individuals. The results of a Peptide Nucleic Acid-ELISA test for M. leprae DNA interpreted by stringent statistical criteria were available for 589 (88.7%) subjects. Thirty-five (5.9%) individuals without clinical signs of leprosy were positive for M. leprae DNA. Seven PCR positive individuals lived in a household where one or two other members were also positive for M. leprae DNA. During a second survey 8 (4.6%) of 175 interpretable PNA-ELISA tests were positive. Of 137 individuals tested twice, only two were positive on both occasions whereas 10 were PCR positive only once. The study confirms the widespread distribution of M. leprae DNA in healthy individuals. The feasibility of curbing possible transmission of subclinical infection needs further consideration.

Original languageEnglish
Pages (from-to)841-848
Number of pages7
JournalEpidemiology and Infection
Volume131
Issue number2
DOIs
Publication statusPublished - 2003

Keywords

  • POLYMERASE CHAIN-REACTION
  • LEPROSY
  • ASSAY

Cite this

Beyene, D., Aseffa, A., Kidane, D., Macdonald, M., Klatser, P. R., Bjune, G. A., ... Harboe, M. (2003). Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia. Epidemiology and Infection, 131(2), 841-848. https://doi.org/10.1017/S0950268803001079

Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia. / Beyene, D.; Aseffa, A.; Kidane, D.; Macdonald, M.; Klatser, P. R.; Bjune, G. A.; Smith, William Cairns Stewart; Harboe, M.

In: Epidemiology and Infection, Vol. 131, No. 2, 2003, p. 841-848.

Research output: Contribution to journalArticle

Beyene, D, Aseffa, A, Kidane, D, Macdonald, M, Klatser, PR, Bjune, GA, Smith, WCS & Harboe, M 2003, 'Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia', Epidemiology and Infection, vol. 131, no. 2, pp. 841-848. https://doi.org/10.1017/S0950268803001079
Beyene, D. ; Aseffa, A. ; Kidane, D. ; Macdonald, M. ; Klatser, P. R. ; Bjune, G. A. ; Smith, William Cairns Stewart ; Harboe, M. / Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia. In: Epidemiology and Infection. 2003 ; Vol. 131, No. 2. pp. 841-848.
@article{d41709b206ec4453b9bd9a2c070088f5,
title = "Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia",
abstract = "The number of registered leprosy patients world-wide has decreased dramatically after extensive application of WHO recommended Multiple Drug Therapy (MDT). The annual number of new cases has, however, been almost unchanged in several populations, indicating that the infection is still present at community level. Nasal carriage of Mycobacterium leprae DNA was studied in Lega Robi village in Ethiopia. MDT had been applied for more than ten years, and 718 residents over 5 years old were eligible for the study. During the first survey nasal swab samples were collected from 664 (92.5{\%}) individuals. The results of a Peptide Nucleic Acid-ELISA test for M. leprae DNA interpreted by stringent statistical criteria were available for 589 (88.7{\%}) subjects. Thirty-five (5.9{\%}) individuals without clinical signs of leprosy were positive for M. leprae DNA. Seven PCR positive individuals lived in a household where one or two other members were also positive for M. leprae DNA. During a second survey 8 (4.6{\%}) of 175 interpretable PNA-ELISA tests were positive. Of 137 individuals tested twice, only two were positive on both occasions whereas 10 were PCR positive only once. The study confirms the widespread distribution of M. leprae DNA in healthy individuals. The feasibility of curbing possible transmission of subclinical infection needs further consideration.",
keywords = "POLYMERASE CHAIN-REACTION, LEPROSY, ASSAY",
author = "D. Beyene and A. Aseffa and D. Kidane and M. Macdonald and Klatser, {P. R.} and Bjune, {G. A.} and Smith, {William Cairns Stewart} and M. Harboe",
year = "2003",
doi = "10.1017/S0950268803001079",
language = "English",
volume = "131",
pages = "841--848",
journal = "Epidemiology and Infection",
issn = "0950-2688",
publisher = "Cambridge University Press",
number = "2",

}

TY - JOUR

T1 - Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia

AU - Beyene, D.

AU - Aseffa, A.

AU - Kidane, D.

AU - Macdonald, M.

AU - Klatser, P. R.

AU - Bjune, G. A.

AU - Smith, William Cairns Stewart

AU - Harboe, M.

PY - 2003

Y1 - 2003

N2 - The number of registered leprosy patients world-wide has decreased dramatically after extensive application of WHO recommended Multiple Drug Therapy (MDT). The annual number of new cases has, however, been almost unchanged in several populations, indicating that the infection is still present at community level. Nasal carriage of Mycobacterium leprae DNA was studied in Lega Robi village in Ethiopia. MDT had been applied for more than ten years, and 718 residents over 5 years old were eligible for the study. During the first survey nasal swab samples were collected from 664 (92.5%) individuals. The results of a Peptide Nucleic Acid-ELISA test for M. leprae DNA interpreted by stringent statistical criteria were available for 589 (88.7%) subjects. Thirty-five (5.9%) individuals without clinical signs of leprosy were positive for M. leprae DNA. Seven PCR positive individuals lived in a household where one or two other members were also positive for M. leprae DNA. During a second survey 8 (4.6%) of 175 interpretable PNA-ELISA tests were positive. Of 137 individuals tested twice, only two were positive on both occasions whereas 10 were PCR positive only once. The study confirms the widespread distribution of M. leprae DNA in healthy individuals. The feasibility of curbing possible transmission of subclinical infection needs further consideration.

AB - The number of registered leprosy patients world-wide has decreased dramatically after extensive application of WHO recommended Multiple Drug Therapy (MDT). The annual number of new cases has, however, been almost unchanged in several populations, indicating that the infection is still present at community level. Nasal carriage of Mycobacterium leprae DNA was studied in Lega Robi village in Ethiopia. MDT had been applied for more than ten years, and 718 residents over 5 years old were eligible for the study. During the first survey nasal swab samples were collected from 664 (92.5%) individuals. The results of a Peptide Nucleic Acid-ELISA test for M. leprae DNA interpreted by stringent statistical criteria were available for 589 (88.7%) subjects. Thirty-five (5.9%) individuals without clinical signs of leprosy were positive for M. leprae DNA. Seven PCR positive individuals lived in a household where one or two other members were also positive for M. leprae DNA. During a second survey 8 (4.6%) of 175 interpretable PNA-ELISA tests were positive. Of 137 individuals tested twice, only two were positive on both occasions whereas 10 were PCR positive only once. The study confirms the widespread distribution of M. leprae DNA in healthy individuals. The feasibility of curbing possible transmission of subclinical infection needs further consideration.

KW - POLYMERASE CHAIN-REACTION

KW - LEPROSY

KW - ASSAY

U2 - 10.1017/S0950268803001079

DO - 10.1017/S0950268803001079

M3 - Article

VL - 131

SP - 841

EP - 848

JO - Epidemiology and Infection

JF - Epidemiology and Infection

SN - 0950-2688

IS - 2

ER -